HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
A New CD38 Monocloncal Antibody Called Isatuximab Gets Closer to the Clinic, with Ravi Vij, MD, Washington University
A New CD38 Monocloncal Antibody Called Isatuximab Gets Closer to the Clinic, with Ravi Vij, MD, Washington University image
HealthTree Podcast for Multiple Myeloma
event Feb 06, 2019 / 11:00AM - 12:00PM MST

Event Description

Ravi Vij, MD
Washington University
Interview Date: February 6, 2019

A new CD38 targeted monoclonal antibody is coming soon to the myeloma clinic. A new drug called isatuximab is making its way through the FDA approval process. Learn how it will be used in combinations, how it could be used in smoldering myeloma, how it is administered and why quad therapies might be a great place to use this drug. Dr. Ravi Vij of Washington University was a Principal Investigator on several of the isatuximab trials and shares more about this new drug. He shares more about MRD testing in myeloma and past successes of drugs in this class. Having more options is always a good thing for multiple myeloma patients and we're happy to see more therapies represent greater progress in the field of myeloma.  

Thanks to our episode sponsor

Schedule & Agenda

Dr. Ravi Vij & Jenny Ahlstrom

Speakers & Moderators

The panelist Ravi Vij, MD, MBA
Ravi Vij, MD, MBA

Ravi Vij, MD, MBA, is Professor of Medicine at the Washington University School of Medicine in the Division of Medical Oncology, Section of Bone Marrow Transplantation and Leukemia. Dr. Vij’s primary academic interests include the treatment of hematologic malignancies and hematopoietic stem cell transplantation. He has research interests in multiple myeloma and AML/myelodysplastic syndromes. Dr. Vij serves on numerous committees including the International Myeloma Working Group (IWMG), the Core Transplant Myeloma and Leukemia Committees of the CALGB, the Steering Committee of the Multiple Myeloma Research Consortium, and the Myeloma Committee of the BMT Clinical Trials Network (CTN). His honors include the Multiple Myeloma Research Foundation Innovator Award (2013) and the Multiple Myeloma Research Consortium Center of Excellence Award (2011). He has authored more than 130 publications in journals such as Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation. He has authored the book Contemporary Management of Multiple Myeloma and several chapters in books, including Multiple Myeloma and Plasma Cell Dyscrasias in the Washington Manual of Oncology. He has served as a review for journals including Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, Experimental Hematology and Haematologica.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us


+1 800 709 1113


Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube